Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $463.83M
• Dividend Yield: N/A
• Average Volume (3M): 164.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 31.30%
• EPS Growth: 32.79%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.39
• Shares Outstanding: 15,862,705
• 10 Day Avg. Volume: 178,321
• 30 Day Avg. Volume: 164,409
• PEG Ratio: 0.68
• Price to Book (P/B): 1.84
• Price to Sales (P/S): 5.27
• P/FCF Ratio: -9.26
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 5.69
• Enterprise Value/Gross Profit: 7.32
• Enterprise Value/Ebitda: -39.91
• 1Y Price Target: $44.33
• Price Target Upside: 51.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -2.01
• Revenue Forecast (FY): $62.95M

• Rating: 45 Neutral
• Price Target: $27.00 ▼(-7.66% Downside)
• Action: Reiterated Date: 03/31/26
• Date: Action: Reiterated 03/31/26

The score is primarily held down by weak financial performance (persistent losses, zero revenue in 2025, and continued cash burn despite low debt). Technicals are neutral-to-soft and valuation is not supportive due to negative earnings and no dividend, while the recent compensation plan is a modest positive but not a fundamental catalyst.

Positive Factors

Low leverage

Low leverage meaningfully reduces solvency and interest-rate pressure for a cash-burning biotech. With limited debt burden the company has greater flexibility to manage development spending and pursue financing or partnerships without immediate debt-service constraints, supporting multi-quarter R&D continuity.

Negative Factors

Persistent cash burn

Consistent negative operating and free cash flow erodes runway and forces reliance on external funding. For a clinical-stage developer this creates ongoing dilution and execution risk, as program advancement or trial timelines can be disrupted if financing windows close or terms deteriorate.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, whic...

Read more

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, whic...

How the Company Makes Money

null...

Assembly Biosciences Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	72.30M	28.52M	7.16M	0.00	6.25M
Gross Profit	72.17M	28.52M	-41.74M	-69.08M	6.25M
EBITDA	-11.99M	-45.29M	-64.20M	-92.52M	-90.58M
Net Income	-6.12M	-40.18M	-61.23M	-93.09M	-129.85M
Balance Sheet
Total Assets	257.59M	119.17M	136.82M	101.79M	191.06M
Cash, Cash Equivalents and Short-Term Investments	248.11M	112.08M	130.25M	91.61M	146.63M
Total Debt	2.63M	3.09M	2.34M	3.46M	6.48M
Total Liabilities	50.84M	85.81M	95.73M	19.13M	22.13M
Stockholders Equity	206.75M	33.36M	41.10M	82.66M	168.93M
Cash Flow
Free Cash Flow	-41.16M	-51.15M	22.49M	-84.56M	-96.49M
Operating Cash Flow	-41.09M	-51.12M	22.74M	-84.46M	-93.40M
Investing Cash Flow	-113.47M	40.17M	-69.14M	90.64M	26.52M
Financing Cash Flow	174.67M	29.45M	13.82M	614.00K	53.06M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.24
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 29.24 is above the 20-day moving average (MA) of 28.51, above the 50-day MA of 28.24, and above the 200-day MA of 27.46, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 52.84 is Neutral, neither overbought nor oversold. The STOCH value of 67.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNTC	49 Neutral	$412.25M	-13.08	-38.92%	―	―	80.95%
ANNX	49 Neutral	$932.36M	-4.03	-101.33%	―	―	-35.62%
LXEO	49 Neutral	$472.68M	-63.66	-67.33%	―	―	4.97%
VOR	47 Neutral	$780.09M	-0.19	72.70%	―	―	-1072.48%
QSI	46 Neutral	$170.65M	-2.15	-43.90%	―	40.20%	-4.07%
ASMB	45 Neutral	$463.83M	-62.28	-5.63%	―	31.30%	32.79%

Assembly Biosciences Corporate Events